N@N

XenoPort to Present at the 28th Annual J.P. Morgan Healthcare Conference

_{//health-fitness.news-articles.net/content/2010/ .. 8th-annual-j-p-morgan-healthcare-conference.html}
^{Published in Health and Fitness on Friday, January 8th 2010 at 21:00 GMT by Market Wire}  

SANTA CLARA, Calif.--([ BUSINESS WIRE ])--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 28^th Annual J.P. Morgan Healthcare Conference. The live presentation will occur at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) on Thursday, January 14, 2010. A replay of the presentation will also be available.

To access the live presentation via the Web, please go to [ www.XenoPort.com ] or to [ https://events.jpmorgan.com ]. The XenoPort presentation can be accessed through the "Conference Webcasts" link for the 28^th Annual J.P. Morgan Healthcare Conference. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one week and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate, XP13512, in collaboration with Astellas Pharma Inc. and GlaxoSmithKline (GSK). Astellas has recently filed a new drug application (NDA) with the Pharmaceuticals and Medical Device Agency in Japan for XP13512 as a potential treatment for restless legs syndrome (RLS). The U.S. Food and Drug Administration is currently reviewing GSK's NDA for XP13512 as a potential treatment for moderate-to-severe primary RLS in the United States. XenoPort's product candidates are also being studied for the potential treatment of gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity and Parkinson's disease.

To learn more about XenoPort, please visit the Web site at [ www.XenoPort.com ].

XenoPort is a registered trademark.

XNPT2G